908 Devices Inc. splits its revenue into 5 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Device Sales at $36.7 million, 65% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
|---|---|---|---|---|---|---|
| Revenue |
61
|
56
|
48
|
50
|
47
|
42
|
| Product And Service |
—
|
—
|
60
share 124.9%
|
—
|
—
|
—
|
| Device Sales |
41
+18.1%
share 68.0%
|
37
+15.7%
share 65.2%
|
32
-5.1%
share 66.4%
|
33
+16.1%
share 66.5%
|
29
share 61.4%
|
—
|
| Recurring |
19
+5.0%
share 31.8%
|
19
+21.9%
share 34.6%
|
16
-3.3%
share 33.4%
|
16
+4.8%
share 32.8%
|
16
share 33.5%
|
—
|
| License And Contract |
—
|
—
|
—
|
—
|
—
|
1
share 2.6%
|
| Contract |
0
+20.0%
share 0.2%
|
0
-11.4%
share 0.2%
|
0
-64.3%
share 0.3%
|
0
-84.4%
share 0.7%
|
2
share 5.1%
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Laboratory Analytical Instruments (SIC 3826)
- Listed as
- MASS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Burlington, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1555279
Other Laboratory Analytical Instruments companies
- Agilent Technologies, Inc. A
- Waters Corp /DE/ WAT
- Illumina, Inc. ILMN
- Mettler Toledo International INC/ MTD
- Revvity, Inc. RVTY
- Avantor, Inc. AVTR
- Bio-Rad Laboratories, Inc. BIO
- Bruker Corp BRKR
Source: SEC EDGAR filings. This is company-reported data, not investment advice.